Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) CFO Thomas Catinazzo sold 17,717 shares of the stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $12.86, for a total value of $227,840.62. Following the transaction, the chief financial officer owned 195,178 shares of the company’s stock, valued at approximately $2,509,989.08. This trade represents a 8.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Thomas Catinazzo also recently made the following trade(s):
- On Tuesday, April 28th, Thomas Catinazzo sold 972 shares of Relay Therapeutics stock. The shares were sold at an average price of $14.79, for a total value of $14,375.88.
- On Tuesday, April 7th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $13.01, for a total value of $230,498.17.
- On Thursday, April 9th, Thomas Catinazzo sold 1,800 shares of Relay Therapeutics stock. The shares were sold at an average price of $15.00, for a total value of $27,000.00.
Relay Therapeutics Trading Down 4.5%
Relay Therapeutics stock opened at $12.20 on Friday. The stock has a market cap of $2.34 billion, a P/E ratio of -7.77 and a beta of 1.74. The stock has a 50 day moving average of $12.47 and a 200-day moving average of $9.54. Relay Therapeutics, Inc. has a 52 week low of $2.75 and a 52 week high of $17.32.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the company. JonesTrading began coverage on Relay Therapeutics in a research note on Tuesday, April 14th. They set a “hold” rating and a $18.00 target price for the company. Wall Street Zen cut Relay Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright raised their price objective on Relay Therapeutics from $19.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Oppenheimer raised their price objective on Relay Therapeutics from $14.00 to $18.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 28th. Finally, Citizens Jmp raised their price objective on Relay Therapeutics from $17.00 to $19.00 and gave the stock a “market outperform” rating in a research note on Tuesday, April 28th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.56.
Check Out Our Latest Analysis on Relay Therapeutics
Institutional Investors Weigh In On Relay Therapeutics
A number of hedge funds have recently added to or reduced their stakes in RLAY. Torren Management LLC bought a new stake in Relay Therapeutics in the fourth quarter valued at $30,000. KBC Group NV bought a new stake in Relay Therapeutics in the first quarter valued at $34,000. Smartleaf Asset Management LLC lifted its stake in Relay Therapeutics by 288.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock valued at $37,000 after buying an additional 3,287 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Relay Therapeutics in the fourth quarter valued at $46,000. Finally, Captrust Financial Advisors bought a new stake in Relay Therapeutics in the second quarter valued at $49,000. 96.98% of the stock is currently owned by institutional investors.
Relay Therapeutics Company Profile
Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.
The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.
Featured Stories
- Five stocks we like better than Relay Therapeutics
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
